Vivos Therapeutics (VVOS) Fireside Chat summary
Event summary combining transcript, slides, and related documents.
Fireside Chat summary
17 Dec, 2025Introduction and agenda
2025 marked a pivotal year with a transformative business model shift, highlighted by the acquisition of Sleep Center of Nevada (SCN) in June.
Background and experience of the speaker
The team has deep experience in dental support organizations and operating medical-dental practices, leveraging this expertise for the new model.
Current industry trends
Obstructive sleep apnea is a major health crisis, with CPAP as the longstanding but unpopular standard treatment.
Home sleep testing is driving a surge in diagnoses, with nearly three million tests expected this year and a growing millennial patient base.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vivos Therapeutics
- Capital-light, high-margin sleep apnea treatment model set for national expansion and rapid growth.VVOS
WTR Insights Conference: Powered by The Small Cap Showcase - Revenue up 70% in Q1 2026, but losses widened and Nasdaq delisting risk remains.VVOS
Q1 2026 - Registers 3.96M shares for resale from warrant exercises, supporting a provider-focused OSA strategy.VVOS
Registration filing - Revenue up 16% to $17.5M as SCN integration drives growth; path to cash flow positive seen.VVOS
Q4 2025 - Registers 3.96M shares for resale, supporting a shift to sleep center acquisitions in the OSA market.VVOS
Registration Filing - Q3 revenue up 17%, gross margin at 60%, with FDA clearance and financing needs ahead.VVOS
Q3 2024 - Q2 2024 revenue up 19%, net loss narrowed, but liquidity and going concern risks persist.VVOS
Q2 2024 - Strategic shift to direct medical engagement and new alliances set stage for major growth in 2025.VVOS
Fireside Chat - Revenue up 9%, operating loss down 35%, and FDA clearances and alliances drive 2025 growth.VVOS
Q4 2024